Madurai News

EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, And Market Forecast–2030

 Breaking News
  • No posts were found

EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, And Market Forecast–2030

August 23
12:46 2021
EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, And Market Forecast–2030
DelveInsight Business Research LLP
DelveInsight’s ‘EGFR Inhibitors-Induced Skin Disorders Market’ report deliver an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

EGFR Inhibitors Induced Skin Disorders Market

The EGFR Inhibitors-Induced Skin Disorders market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM EGFR Inhibitors-Induced Skin Disorders market size from 2021 to 2030. The Report also covers current EGFR Inhibitors-Induced Skin Disorders treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

EGFR Inhibitors-Induced Skin Disorders Market Outlook

Inhibitors of the epidermal growth factor receptor (EGFR) are used in a growing range of tumor types to improve clinical outcomes. EGFR may be inhibited with anti-EGFR-specific monoclonal antibodies or small-molecule tyrosine kinase inhibitors. Dermatologic toxic effects are the most common side-effects associated with anti-EGFR therapy.

The treatment of EGFR inhibitor-related skin reactions is not standardized, and accounts in the literature are based on local practice and mainly derived from personal, albeit extensive, experience. Currently, there is no approved therapy specific for anti-EGFR induced skin diseases in the US, EU, and Japan. The off-label therapeutic options used for anti-EGFR induced skin diseases are sunscreen, emollients and soap substitutes, antibiotics, antihistamines, topical steroids, and cosmetics.

In contrast to acne vulgaris, topical antibiotic treatment with erythromycin, metronidazole, or nadifloxacin twice daily is recommended for early-stage and low-grade papulopustular skin reactions. Cream or lotion preparations are preferred to take advantage of an additional moisturization effect. Fissures are treated topically with propylene glycol 50%. For grade 3 rash, oral corticosteroids (methylprednisolone dose pack or prednisone 0.5 mg/kg for 7 days) are also considered to be beneficial.

The market has a critical unmet need for approved therapies specific to EGFR inhibitor-induced skin disorders. The treatment is mainly based on off-label therapies with limited safety and efficacy data. Corticosteroid use is also often limited due to their toxicity on long-term use. The patient population of cancers and EGFR inhibitor utilization is expected to increase throughout the forecast period (2021–2030). These may contribute to the rise of the patient population of EGFR inhibitor-induced skin disorders. With this and the expected launch of emerging therapy Imsidolimab (ANB019), the market is expected to show a significant boost during the forecast period.

Key Findings

  • The market size of EGFR Inhibitors-induced Skin Disorders in the 7MM was estimated to be USD 57 million in 2020, and with the expected approval of Imsidolimab (ANB019); and with an increased incidence of cancers with EGFR mutation, the market is expected to upsurge by 2030 at a CAGR of 18.25% for the study period of 2018–2030.
  • The United States holds the largest market share of the EGFR Inhibitors-induced Skin Disorders among the 7MM countries, which accounts for 49.59% (USD 28 million) of the total 7MM market, in 2020.
  • Among the EU-5 countries, Germany (USD 5 million) had the highest market share, followed by France (USD 4 million) and Italy (USD 4 million), in 2020.
  • Japan holds the second-largest share of the 7MM EGFR Inhibitors-induced Skin Disorders market with a market size of USD 9 million in 2020, which is expected to rise by 2030 at a CAGR of 17.05% for the study period of 2018–2030.
  • EGFR Inhibitors-Induced Skin Disorders’ current treatment market is limited to topical steroid cream or ointment, local and systemic therapies, and others.
  • Imsidolimab (ANB019) is expected to reach the market by 2025, generating a market size of USD 3 million in the launch year. As the current market is mainly based on off-label therapies, it might capture a large market share of current therapies by 2030.

Request for sample pages @ EGFR Inhibitors Induced Skin Disorders Market Size 

Table of contents

1. Key Insights

2. Report Introduction

3. EGFR Inhibitors-induced Skin Disorders Market Overview at a Glance

3.1. Market Share (%) Distribution of EGFR Inhibitors-induced Skin Disorders in 2018

3.2. Market Share (%) Distribution of EGFR Inhibitors-induced Skin Disorders in 2030

4. Executive Summary of EGFR Inhibitors-Induced Skin Disorders

5. Disease Background and Overview

5.1. Introduction

5.2. Side Effects of EGFR Inhibitor Treatment

5.3. Mechanisms Underlying EGFR Inhibitors Induced Cutaneous Disorders

5.3.1. Skin inflammation, or rash and folliculitis

5.3.2. Nail and periungual toxicity

5.3.3. Barrier defect/xerosis

5.3.4. Antimicrobial defense/infections

5.3.5. Hair alterations

5.4. Diagnosis

5.4.1. Differential Diagnosis of EGFR-induced rash

5.4.2. Diagnosis and patient education of drug-induced hair disorders

5.4.3. Diagnosis of xerosis cutis

5.5. Treatment

5.5.1. Treatment of acneiform rash

5.5.2. Treatment of nail changes

5.5.3. Treatment of xerotic and eczematous skin

5.5.4. Treatment of pruritus/itching

5.5.5. Treatment of fissures

5.6. Treatment Algorithm

5.7. Management Guidelines and Treatment Recommendations

5.7.1. General treatment recommendations

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.2.1. NSCLC

6.2.2. Colorectal Cancer

6.2.3. Pancreatic Cancer

6.2.4. Head and Neck Cancer

6.2.5. Breast Cancer

6.3. Total Cases of Cancer on EGFR Inhibitors in the 7MM

6.4. Total Cases on EGFR Inhibitors in the 7MM

6.5. Total Cases of EGFR Induced Skin Disorders in the 7MM

6.6. Total Cases of EGFR Induced Skin Disorders by Cancer Type in the 7MM

6.7. Epidemiology of EGFR Inhibitors-induced Skin Disorders

6.7.1. Assumptions and Rationale for NSCLC

6.7.2. Assumptions and Rationale for Colorectal Cancer

6.7.3. Assumptions and Rationale for Pancreatic Cancer, Breast Cancer, and Head and Neck Cancer

6.8. The United States

6.8.1. Total Number of Cases on EGFR inhibitors by Cancer Type in the US

6.8.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in the US

6.9. EU5

6.9.1. Germany

6.9.1.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Germany

6.9.1.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Germany

6.9.2. France

6.9.2.1. Total Number of Cases on EGFR inhibitors by Cancer Type in France

6.9.2.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in France

6.9.3. Italy

6.9.3.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Italy

6.9.3.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Italy

6.9.4. Spain

6.9.4.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Spain

6.9.4.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Spain

6.9.5. The United Kingdom

6.9.5.1. Total Number of Cases on EGFR inhibitors by Cancer Type in the United Kingdom

6.9.5.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in the United Kingdom

6.10. Japan

6.10.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Japan

6.10.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Japan

7. Patient Journey

8. Emerging Therapies

8.1. Key Cross Competition

8.2. AC-701 Topical Gel 0.3%: TWi Pharmaceuticals

8.2.1. Drug Description

8.2.2. Other Developmental Activities

8.2.3. Clinical Development

8.2.4. Clinical Trials Information

8.2.5. Product Profile

8.3. ATR-04: Azitra Inc.

8.3.1. Drug Description

8.3.2. Other Developmental Activities

8.3.3. Clinical Development

8.3.4. Clinical Trials Information

8.3.5. Product Profile

8.4. Imsidolimab (ANB019): AnaptysBio Inc.

8.4.1. Drug Description

8.4.2. Other Developmental Activities

8.4.3. Clinical Development

8.4.4. Clinical Trials Information

8.4.5. Safety and Efficacy

8.4.6. Product Profile

8.5. LUT014: Lutris Pharma Ltd.

8.5.1. Drug Description

8.5.2. Other Developmental Activities

8.5.3. Clinical Development

8.5.4. Clinical Trials Information

8.5.5. Product Profile

8.6. HT-001/WEG232 (Aprepitant): Hoth Therapeutics

8.6.1. Drug Description

8.6.2. Other Developmental Activities

8.6.3. Product Profile

9. EGFR Inhibitors-induced Skin Disorders: Seven Major Market Analysis

9.1. Key Findings

9.2. Methodology of EGFR Inhibitors-induced Skin Disorders Market

9.3. Market Size of EGFR Inhibitors-induced Skin Disorders in the 7MM

9.4. Market Size of EGFR Inhibitors-induced Skin Disorders by Therapies

9.5. Key Market Forecast Assumptions

9.6. 7MM Market Outlook

9.7. United States Market Size

9.7.1. Total Market Size of EGFR Inhibitors-Induced Skin Disorders in the United States

9.7.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in the United States

9.8. EU-5 Market Size

9.8.1. Germany

9.8.1.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in Germany

9.8.1.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in Germany

9.8.2. France

9.8.2.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in France

9.8.2.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in France

9.8.3. Italy

9.8.3.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in Italy

9.8.3.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in Italy

9.8.4. Spain

9.8.4.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in Spain

9.8.4.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in Spain

9.8.5. United Kingdom

9.8.5.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in the United Kingdom

9.8.5.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in the United Kingdom

9.9. Japan

9.9.1. Total Market size of EGFR Inhibitors-Induced Skin Disorders in Japan

9.9.2. Market Size of EGFR Inhibitors-Induced Skin Disorders by Therapies in Japan

10. Market Drivers

11. Market Barriers

12. SWOT Analysis

13. Unmet Needs

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/